טוען...
Sorafenib: Where Do We Go from Here?
The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3605708/ https://ncbi.nlm.nih.gov/pubmed/20578152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.23633 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|